Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
Americans are catching up on healthcare procedures missed during the COVID-19 pandemic, particularly heart procedures and orthopedic surgeries. The trend ...
KalVista Pharmaceuticals achieves key goals in late-stage study for hereditary angioedema therapy, demonstrating significant efficacy of sebetralstat. FDA approval filing ...
Global medical technology company, Baxter International, has announced a quarterly cash dividend of $0.29 per share. This demonstrates their commitment ...
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...